中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

113 records (took 0.016 seconds)

    LFA-1 SIGNALLING MEDIATOR FOR USE IN CANCER THERAPY
    32.
    发明公开
    LFA-1 SIGNALLING MEDIATOR FOR USE IN CANCER THERAPY 审中-公开

    公开(公告)号：US20240010726A1

    公开(公告)日：2024-01-11

    申请号：US18021323

    申请日：2021-08-17

    Applicant: Universität Basel

    Inventor： Jonas LÖTSCHER ,  Christoph HESS

    IPC: C07K16/28 ,  A61P35/00 ,  A61K9/00

    CPC classification number: C07K16/2818 ,  A61P35/00 ,  A61K9/0019

    Abstract: The present invention relates to an LFA-1 signalling mediator with moderate LFA-1 stabilization properties for use in cancer immunotherapy or a composition for use in cancer immunotherapy comprising an immune system modulator, wherein the immune system modulator enhances the immune response against cancer, and an LFA-1 signalling mediator with moderate LFA-1 stabilization properties wherein the LFA-1 signalling mediator selectively and significantly enhances the anti-cancer immune response. The composition may comprise a carrier for target delivery of the composition.

    HEMOSTATIC ELASTIN-LIKE POLYPEPTIDES
    33.
    发明公开
    HEMOSTATIC ELASTIN-LIKE POLYPEPTIDES 审中-公开

    公开(公告)号：US20240010682A1

    公开(公告)日：2024-01-11

    申请号：US18042001

    申请日：2021-08-17

    Applicant: UNIVERSITÄT BASEL

    Inventor： Michael Adam NASH ,  Ivan UROSEV

    IPC: C07K7/08 ,  A61K38/10 ,  A61P7/04

    CPC classification number: C07K7/08 ,  A61K38/10 ,  A61P7/04

    Abstract: The present invention relates to a hemostatic elastin-like polypeptide comprising a glutamine embedded in a Q-block sequence and, optionally, a lysine embedded in a K-block sequence. Under physiological setting, the Q-block sequence and the K-block sequence are recognized by human transglutaminase factor XIIIa and crosslinked with fibrin networks. The present invention also relates to the medical use of the polypeptide, to a nucleic acid sequence encoding the polypeptide, to an expression vector comprising the nucleic acid sequence, and to a cell comprising the nucleic acid sequence or the expression vector.

    DEVICE-INDEPENDENT QUANTUM KEY DISTRIBUTION
    34.
    发明公开
    DEVICE-INDEPENDENT QUANTUM KEY DISTRIBUTION 审中-公开

    公开(公告)号：US20230353350A1

    公开(公告)日：2023-11-02

    申请号：US17998661

    申请日：2021-05-12

    Applicant: ETH ZURICH ,  UNIVERSITÄT BASEL

    Inventor： Melvyn HO ,  Pavel SEKATSKI ,  Jean-Daniel BANCAL ,  Nicolas SANGOUARD ,  Ernest TAN ,  Renato RENNER

    IPC: H04L9/08

    CPC classification number: H04L9/0858

    Abstract: The invention relates to a method for device-independent quantum key generation and distribution between a first and a second receiver, the method comprising the steps of:

    a) Generating an entangled information pair, comprising two entangled quantum moieties that have at least one quantum state entangled with each other, such as a polarization,
    b) Transmitting a first entangled quantum moiety of the two entangled quantum moieties to the first receiver (A) and a second entangled quantum moiety of the two entangled quantum moieties to the second receiver (B), and measuring the quantum states of the entangled moieties with a set of selected detection settings chosen randomly at each receiver
    c) In a modification step, assigning each measurement value b1 measured with a detection setting B1 a complementary value





    b
    1
    ∗





    according to a noise-probability p, wherein the noise-probability p is larger than 0 and lower than 1, such that a modified plurality of measurement values







    b
    1


    ˜





    is obtained,
    d) Generating a final shared quantum key from the modified plurality measurements values







    b
    1


    ˜





    and from a plurality of measurement values a0 measured with a detection setting A0 at the first receiver (A).

    ARENAVIRUSES AS VECTORS
    39.
    发明申请
    ARENAVIRUSES AS VECTORS 有权

    公开(公告)号：US20220380805A1

    公开(公告)日：2022-12-01

    申请号：US17772996

    申请日：2020-11-06

    Applicant: UNIVERSITÄT BASEL

    Inventor： Daniel PINSCHEWER ,  Weldi Bonilla PINSCHEWER

    IPC: C12N15/86 ,  A61K39/12

    Abstract: The present application relates to arenavirus particles containing a genome engineered such that an arenaviral open reading frame (“ORF”) is sequestered into two or more functional fragments and these fragments are expressed from two or more viral mRNA transcripts. The arenavirus particles described herein are genetically stable and provide high-level transgene expression. In certain embodiments, the arenavirus particles are tri-segmented. In particular, described herein is a nucleotide sequence comprising one or more ORFs comprising a nucleotide sequence encoding a functional fragment of arenavirus GP, NP, L or Z. Also described herein is an arenavirus particle containing a genome engineered such that an arenaviral ORF is sequestered into two or more functional fragments and these fragments are expressed from two or more viral mRNA transcripts. Also described herein is an arenavirus genomic or antigenomic segment engineered such that the transcription thereof results in one or more mRNA transcripts comprising a nucleotide sequence encoding a functional fragment of arenavirus GP, NP, L or Z. The arenavirus particles described herein may be suitable for vaccines and/or treatment of diseases and/or for the use in immunotherapies.

Patent Agency Ranking